10
Participants
Start Date
August 26, 2021
Primary Completion Date
July 4, 2024
Study Completion Date
September 16, 2024
Blinatumomab
Participants will receive blinatumomab continuous IV infusion for a maximum of 4 cycles. Each cycle is 6 weeks in duration consisting of 4 weeks of treatment and 2 weeks of rest.
Current Wearable Heatlth Monitoring System (CWHMS)
The study will use the CWHMS device to monitor participants' vital signs while they are at home.
Mount Sinai Hospital, New York
University of Rochester Cancer Center, Rochester
University of Virginia Health System, Charlottesville
Wake Forest University Health Sciences, Winston-Salem
Saint Francis Hospital, Inc, Greenville
Mayo Clinic, Jacksonville
Adventist Health System/Sunbelt, Inc d/b/a AdventHealth Orlando, Orlando
Advocate Lutheran General Hospital, Park Ridge
University of Nebraska Medical Center, Omaha
University of California Los Angeles, Los Angeles
City of Hope National Medical Center, Duarte
University of California Irvine, Orange
Lead Sponsor
Amgen
INDUSTRY